한글목차

길랭 바레 증후군 진단 세계 시장은 2024년에 1억 5,095만 달러로 평가되며, 예측 기간 동안 5.12%의 CAGR로 2030년에는 1억 7,342만 달러에 달할 것으로 예상됩니다.

길랭 바레 증후군(GBS)은 신체의 면역 체계가 실수로 말초신경계를 공격하여 근력 약화, 무감각, 마비, 심한 경우 마비를 유발하는 희귀한 중증 신경 질환입니다. 조기에 정확한 진단은 효과적인 관리와 치료를 위해 매우 중요하지만, 이 질환의 다양성과 다른 신경질환과 중복되는 증상으로 인해 그 식별이 쉽지 않습니다.

GBS를 진단하기 위해서는 먼저 자세한 임상 검사와 병력 청취가 필요합니다. 의사는 일반적으로 하반신에서 시작하여 상체로 진행되는 근력 약화의 발현과 진행을 평가합니다. 반사 신경은 종종 저하되거나 사라지는데, 이는 GBS의 두드러진 특징입니다. 또한 무감각, 통증과 같은 감각 장애, 혈압 변동, 심장 박동 이상과 같은 자율신경 장애를 호소할 수 있으며, GBS는 종종 선행 감염에 의해 발병하는 경우가 많기 때문에 의사는 호흡기 감염이나 위장 장애와 같은 최근 질병에 대해 질문합니다.

신경전도검사(NCS)와 근전도검사(EMG)는 GBS를 확인하는 데 필수적인 진단 수단으로 NCS는 말초신경의 전기 신호의 속도와 강도를 측정하며, GBS에서는 신경의 탈수초화 및 축삭 손상으로 인해 이러한 신호가 느려지거나 차단됩니다. 신경 자극에 대한 근육의 반응을 평가하는 EMG는 GBS를 다른 신경근 질환과 구별하는 데 도움이 됩니다. 이러한 검사 결과는 급성 염증성 탈수초성 다발성 신경병증(AIDP), 급성 운동축삭신경병증(AMAN) 등 GBS의 아형에 대한 귀중한 정보를 제공합니다.

뇌와 척수를 둘러싸고 있는 뇌척수액(CSF)을 분석하기 위해 요추 천자(척수 천자)를 시행하는 경우가 많으며, GBS의 경우, 척수액 분석에서 일반적으로 알부민 세포학적 해리로 알려진 백혈구의 현저한 증가 없이 단백질 수치의 증가가 관찰됩니다. 그러나 이러한 특징적인 증상은 질환 초기에 나타나지 않을 수 있으며, 임상적으로 의심되는 경우 반복적인 검사가 필요합니다.

시장 촉진요인

길랭 바레 증후군 발생률 증가

주요 시장 과제

제한된 인지도와 오진

주요 시장 동향

진단 기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 길랭 바레 증후군 진단 시장에 미치는 영향

제5장 세계의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 검사별(요추 천자, 근전도 검사, 기타)
  • 최종 용도별(병원·진료소, 진단 연구소, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제7장 유럽의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 길랭 바레 증후군 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(있는 경우)
• 테스트 기동(있는 경우)
• 최근 동향

제13장 세계의 길랭 바레 증후군 진단 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Cadwell Industries, Inc
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Bionen s.r.l.
• Deymed Diagnostic s.r.o.
• Neurosoft Ivanovo, Russia
• Alpine Biomedicals Pvt Ltd.
• EMS Handels Gesellschaft m.b.H.
• Rochester Electro-Medical, Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

Global Guillain-Barre Syndrome Diagnostics Market was valued at USD 150.95 Million in 2024 and is expected to reach USD 173.42 Million by 2030 with a CAGR of 5.12% during the forecast period. Guillain-Barre Syndrome (GBS) is a rare but serious neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, numbness, and in severe cases, paralysis. Early and accurate diagnosis is critical for effective management and treatment, but the condition's variability and overlapping symptoms with other neurological disorders make its identification challenging.

The first step in diagnosing GBS involves a detailed clinical examination and patient history. Physicians assess the onset and progression of muscle weakness, typically starting in the lower limbs and ascending toward the upper body. Reflexes are often diminished or absent, a hallmark characteristic of GBS. Patients may also report sensory disturbances, such as tingling or pain, and autonomic dysfunction, including blood pressure fluctuations and abnormal heart rhythms. Since GBS is often triggered by a preceding infection, doctors inquire about recent illnesses such as respiratory infections or gastrointestinal disturbances.

Nerve conduction studies (NCS) and electromyography (EMG) are essential diagnostic tools for confirming GBS. NCS measures the speed and strength of electrical signals in the peripheral nerves. In GBS, these signals are slowed or blocked due to nerve demyelination or axonal damage. EMG, which assesses muscle response to nerve stimulation, can help distinguish GBS from other neuromuscular conditions. The results of these tests provide valuable insights into the subtype of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) or acute motor axonal neuropathy (AMAN).

A lumbar puncture (spinal tap) is often performed to analyze cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. In GBS, CSF analysis typically reveals elevated protein levels without a significant increase in white blood cells, a finding known as albuminocytological dissociation. However, this hallmark feature may not be present in the early stages of the disease, requiring repeated testing if clinical suspicion remains high.

Key Market Drivers

Rising Incidence of Guillain-Barre Syndrome

Guillain-Barre Syndrome (GBS) is an autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. The global rise in the incidence of GBS has become a significant concern for healthcare providers, prompting increased demand for accurate and timely diagnostic solutions. The growing number of GBS cases worldwide, fueled by viral infections, vaccinations, and other autoimmune triggers, is a key driver of the expanding Guillain-Barre Syndrome diagnostics market. According to the National Organization for Rare Disorders (NORD), Guillain-Barre Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.

One of the major factors contributing to the rising incidence of GBS is the increased prevalence of viral infections such as Zika virus, cytomegalovirus, and Epstein-Barr virus, which have been linked to the onset of the syndrome. Additionally, seasonal influenza and COVID-19 infections have also been associated with a higher risk of developing GBS. The correlation between these infections and GBS has intensified the need for early and precise diagnostic tools, including cerebrospinal fluid (CSF) analysis, electromyography (EMG), and nerve conduction studies (NCS), which are essential for confirming GBS and differentiating it from other neurological disorders.

Advancements in diagnostic technologies are further propelling market growth. Innovations in biomarker detection, molecular diagnostics, and imaging techniques have enhanced the ability to identify GBS in its early stages, leading to improved patient outcomes. Additionally, artificial intelligence (AI)-driven diagnostic solutions are being developed to enhance the accuracy and efficiency of GBS detection. These technological advancements are helping to meet the growing demand for rapid and reliable diagnostic procedures, further expanding the market.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges in the GBS diagnostics market is the lack of awareness among healthcare providers and the general population. Guillain-Barre Syndrome presents with symptoms similar to other neurological disorders, such as multiple sclerosis and myasthenia gravis, leading to frequent misdiagnosis or delayed identification. This delay in diagnosis can significantly impact patient outcomes, as early intervention is critical in managing the condition effectively.

Key Market Trends

Technological Advancements in Diagnostics

One of the key trends shaping the GBS diagnostics market is the advancement in diagnostic technologies. Modern electrophysiological tests, such as NCS and EMG, are becoming more precise and efficient, aiding in the differentiation of GBS subtypes. Additionally, biomarker research has gained traction, with efforts focused on identifying specific autoantibodies and inflammatory markers that could improve the accuracy of GBS diagnosis. The integration of artificial intelligence (AI) and machine learning in medical imaging and electrophysiology has the potential to enhance diagnostic efficiency, reducing the time needed for clinical decision-making.

Key Market Players

• Cadwell Industries, Inc
• Natus Medical Incorporated
• Nihon Kohden Corporation
• Medtronic plc
• Bionen s.r.l.
• Deymed Diagnostic s.r.o.
• Neurosoft Ivanovo, Russia
• Alpine Biomedicals Pvt Ltd.
• EMS Handels Gesellschaft m.b.H.
• Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test:

• Lumbar Puncture
• Electromyography
• Others

Guillain-Barre Syndrome Diagnostics Market, By End use:

• Hospitals And Clinics
• Diagnostic Laboratories
• Others

Guillain-Barre Syndrome Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Guillain-Barre Syndrome Diagnostics Market

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
  • 5.2.2. By End Use (Hospitals And Clinics, Diagnostic Laboratories, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test
      • 6.3.3.2.2. By End Use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test
      • 7.3.5.2.2. By End Use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test
      • 8.3.5.2.2. By End Use

9. South America Guillain-Barre Syndrome Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Guillain-Barre Syndrome Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Test Launches (If Any)
• 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Cadwell Industries, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Natus Medical Incorporated
• 15.3. Nihon Kohden Corporation
• 15.4. Medtronic plc
• 15.5. Bionen s.r.l.
• 15.6. Deymed Diagnostic s.r.o.
• 15.7. Neurosoft Ivanovo, Russia
• 15.8. Alpine Biomedicals Pvt Ltd.
• 15.9. EMS Handels Gesellschaft m.b.H.
• 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer